---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-035806"
form_type: "8-K"
ticker: "DMRA"
cik: "0001800315"
company_name: "Damora Therapeutics, Inc."
filed_at: "2021-07-06T23:59:59+00:00"
generated_at: "2026-06-30T07:21:05.392575+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Galecto adopts executive Separation Benefits Plan with tiered severance for C-Level officers

## Summary
- Plan covers CEO, CFO, COO, CMO, General Counsel and other designated employees.
- Non-Sale termination: CEO receives 15 months base salary; other C-Level get 12 months; prorated bonus and equity vesting during severance period.
- Sale Event termination: CEO gets 18 months lump sum; other C-Level get 12 months lump sum; bonus of 150%/100% of target; 100% equity vesting.
- Plan supersedes all prior severance agreements and requires a release of claims, non-disparagement, and cooperation as conditions.
- Board may amend or terminate plan with 18 months' notice before a Sale Event; post-Sale Event amendments restricted for 24 months.

## SEC filing metadata
- accession: 0001564590-21-035806
- form_type: 8-K
- ticker: DMRA
- cik: 0001800315
- company_name: Damora Therapeutics, Inc.
- filed_at: 2021-07-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800315/000156459021035806/0001564590-21-035806-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800315/000156459021035806/glto-8k_20210706.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-035806
- JSON: https://secwatch.observer/filing/0001564590-21-035806.json
- Plain text: https://secwatch.observer/filing/0001564590-21-035806.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.